Cannabidiol for the treatment of cannabis withdrawal syndrome: A case report

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 2, 2013, Pages 162-164

  Crippa, J A S ^a   Hallak, J E C ^a   Machado De Sousa, J P ^a   Queiroz, R H C ^a   Bergamaschi, M ^a   Chagas, M H N ^a   Zuardi, A W ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

(MeSH); cannabidiol; cannabis; substance withdrawal syndrome

Indexed keywords

CANNABIDIOL; CANNABIS;

ADULT; ARTICLE; CANNABIS ADDICTION; CANNABIS SMOKING; CANNABIS WITHDRAWAL SYNDROME; CASE REPORT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; TREATMENT DURATION; WITHDRAWAL SYNDROME; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

ADULT; CANNABIDIOL; CANNABIS; FEMALE; HUMANS; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 84874980235     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12018     Document Type: Article

References (34)

1. Budney AJ, Hughes JR,. The cannabis withdrawal syndrome. Curr Opin Psychiatry, 2006; 19: 233-238.
2. Budney AJ, Hughes JR, Moore BA, Vandrey R,. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry, 2004; 161: 1967-1977.
3. Budney AJ, Vandrey RG, Stanger C,. [Pharmacological and psychosocial interventions for cannabis use disorders]. Rev Bras Psiquiatr, 2010; 32 (Suppl 1): S46-S55.
4. Vandrey R, Haney M,. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs, 2009; 23: 543-553.
5. Gonzalez S, Cebeira M, Fernandez-Ruiz J,. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav, 2005; 81: 300-318.
6. Villares J,. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience, 2007; 145: 323-334.
7. Cooper ZD, Haney M,. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol, 2008; 13: 188-195.
8. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW,. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology, 2004; 29: 158-170.
9. Budney AJ, Roffman R, Stephens RS, Walker D,. Marijuana dependence and its treatment. Addict Sci Clin Pract, 2007; 4: 4-16.
10. Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW,. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology, 2005; 181: 237-243.
11. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol, 2001; 134: 845-852.
12. Zuardi AW,. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr, 2008; 30: 271-280.
13. Crippa JA, Zuardi AW, Martin-Santos R, Bhattacharyya S, Atakan Z, McGuire P, Fusar-Poli P,. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol, 2009; 24: 515-523.
14. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS,. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol, 1993; 7: 82-88.
15. Crippa JA, Zuardi AW, Garrido GE, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology, 2004; 29: 417-426.
16. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry, 2009; 66: 95-105.
17. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 2011; 36: 1219-1226.
18. Moreira FA, Aguiar DC, Guimaraes FS,. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry, 2006; 30: 1466-1471.
19. Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW,. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology, 1990; 100: 558-559.
20. Zanelati TV, Biojone C, Moreira FA, Guimaraes FS, Joca SR,. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol, 2010; 159: 122-128.
21. Zuardi AW, Guimaraes FS, Moreira AC,. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res, 1993; 26: 213-217.
22. Monti JM,. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology, 1977; 55: 263-265.
23. Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colin R,. The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent. Behav Neurosci, 2008; 122: 1378-1382.
24. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav, 1991; 40: 701-708.
25. Stempliuk Vde A, Barroso LP, Andrade AG, Nicastri S, Malbergier A,. Comparative study of drug use among undergraduate students at the University of Sao Paulo - Sao Paulo campus in 1996 and 2001. Rev Bras Psiquiatr, 2005; 27: 185-193.
26. Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA,. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf, 2011; 6: 237-249.
27. First MB, Spitzer RL, Gibbon M, Williams JBM, eds. 1997. Structured clinical interview for DSM-IV axis I disorders-Clinican version (SCID-CV). Washington D.C: American Psychiatry Press.
28. Budney AJ, Hughes JR, Moore BA, Novy PL,. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry, 2001; 58: 917-924.
29. Beck AT, Epstein N, Brown G, Steer RA,. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol, 1988; 56: 893-897.
30. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J,. An inventory for measuring depression. Arch Gen Psychiatry, 1961; 4: 561-571.
31. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry, 2012; 20 (2): e94.
32. Clapper JR, Mangieri RA, Piomelli D,. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology, 2009; 56 (Suppl 1): 235-243.
33. Tyndale RF, Payne JI, Gerber AL, Sipe JC,. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians. Am J Med Genet B Neuropsychiatr Genet, 2007; 144B: 660-666.
34. Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R,. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology, 2004; 175: 360-366.